Viewing nowPregabalin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Vivozon Pharmaceutical Co., Ltd.

MFDS item code 201603689 · Approved 2016.06.21 · Insurance code 658203240
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. Additionally, it can be used as an adjunct for patients with epilepsy who experience partial seizures or have generalized symptoms. It is also effectively used for patients with fibromyalgia. In summary, this drug helps relieve neuropathic pain, manage epilepsy, and improve symptoms of fibromyalgia.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration schedule Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: Supplemental dose refers to a dose administered once as an additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
Careful monitoring for suicidal thoughts or behaviors, depression onset or worsening, and abnormal changes in mood and behavior is required during treatment with this medication. Patients with hypersensitivity to this medication should not take it. Diabetic patients may experience weight gain while taking this medication, which may require adjustment of blood sugar control medications. If allergic reactions such as angioedema occur, discontinue use immediately. Elderly patients should be particularly cautious as dizziness or drowsiness may occur after taking this medication, especially during the initial phase. Vision blurriness or changes in vision may occur; these symptoms can improve after stopping the medication. Sudden discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, and should therefore be tapered gradually under a physician's guidance. There is a potential risk of drug abuse or dependence, so patients with a history of drug abuse should be particularly careful and report any unusual signs immediately. Patients with impaired renal function may require dose adjustments. Patients with heart disease should exercise caution while taking this medication, especially those with congestive heart failure. The risk of respiratory depression may increase when used in conjunction with other central nervous system depressants, so caution is advised. This medication should not be used during early pregnancy due to the risk of congenital malformations, and sexually active women should utilize effective contraceptive methods. Breastfeeding women should consider discontinuing nursing or the medication as this drug can be transmitted through breast milk. Dizziness or drowsiness may occur, hence caution is advised when driving or operating dangerous machinery. Severe skin reactions may occur; if symptoms such as skin rashes arise, discontinue use immediately and consult a doctor. In the event of an overdose, symptoms such as confusion, drowsiness, depression, and agitation may occur, and treatment such as hemodialysis may be necessary. Special caution is necessary for children, the elderly, and patients with impaired renal function while taking this medication. This drug has minimal pharmacokinetic interactions with other drugs, but caution is advised as side effects may worsen when taken with other central nervous system depressants. Adhering to these precautions will help ensure safe therapeutic outcomes.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly closed container. It is recommended to maintain the storage temperature between 15 to 30 degrees Celsius.
A white hard capsule containing white powder
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Vivozon Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.